Harmony 2025 Q3 Earnings Strong Revenue and Net Income Growth Beats Estimates

martes, 4 de noviembre de 2025, 11:44 pm ET1 min de lectura
HRMY--
Harmony (HRMY) reported robust fiscal 2025 Q3 results, . , reflecting strong demand for its flagship drug WAKIX and momentum in its pipeline.

Revenue

, . This growth was driven by record patient additions for WAKIX, .


Earnings/Net Income

, , , . The company’s profitability strengthened, . .


Price Action

, , . , 2025, .


Post-Earnings Price Action Review

, . . . , , . <visualization dataurl="https://cdn.ainvest.com/news/visual/visual_components/viz_wu1dk5nh.json"></visualization>


CEO Commentary

, . .


Guidance

, . , .


Additional News

1. Pipeline Advancement, .

2. Commercial Momentum, , .

3. Financial Strength, .



Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios